Weitere Artikel dieser Ausgabe durch Wischen aufrufen
Dr. Dominik Spira and Priv.-Doz. Dr. Kristina Norman contributed equally to this work.
Sarcopenia describes the age-associated loss of muscle mass, strength and function. The aim of this study was to compare the prevalence of sarcopenia in a cohort of community dwelling elderly people living in Berlin, Germany, according to the criteria proposed by current consensus statements and to study the respective impact on self-reported physical performance.
This study included 1405 participants from the Berlin aging study II (BASE-II). The appendicular skeletal muscle mass index (SMI) was assessed with dual energy X-ray absorptiometry (DXA), muscle strength was measured by hand grip strength and the timed up and go” test (TUG) was performed as a functional parameter to reflect mobility.
The prevalence of sarcopenia was 24.3 % in terms of reduced SMI only and considerably lower for sarcopenia with reduced grip strength (4.1 %) and sarcopenia with limited mobility (2.4 %). Only 0.6 % of the participants fulfilled all three criteria. Of the subjects with a normal SMI, 8.6 % had reduced grip strength and 5.1 % had limited mobility, whereas 1.3 % subjects fulfilled both criteria. Participants with reduced strength or function reported severe difficulties in performing physical tasks significantly more often than participants with normal or reduced SMI alone (p <0.029–p <0.0001).
In BASE-II low skeletal muscle mass was much more frequent than reduced grip strength or poor function. Reduced strength and function were found to be associated with a greater impact on physical performance than reduced muscle mass. Low SMI does not seem to be a prerequisite for low strength or limitations in mobility.
Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten
Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:
Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR et al (1988) Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol 147(8):755–763 CrossRef
Bijlsma AY, Meskers CG, Ling CH, Narici M, Kurrle SE, Cameron ID et al (2013) Defining sarcopenia: the impact of different diagnostic criteria on the prevalence of sarcopenia in a large middle aged cohort. Age (Dordr) 35(3):871–881 CrossRef
Bohannon RW (2006) Grip strength predicts outcome. Age Ageing 35(3):320 CrossRef
Lauretani F, Russo CR, Bandinelli S, Bartali B, Cavazzini C, Di IA et al (2003) Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia. J Appl Physiol (1985) 95(5):1851–1860 CrossRef
Maden-Wilkinson TM, Degens HF, Jones DA FAU, McPhee JS (2013) Comparison of MRI and DXA to measure muscle size and age-related atrophy in thigh muscles. J Musculoskelet Neuronal Interact 13:320–328 PubMed
Patel HP, Syddall HE, Jameson K, Robinson S, Denison H, Roberts HC et al (2013) Prevalence of sarcopenia in community-dwelling older people in the UK using the European Working Group on Sarcopenia in Older People (EWGSOP) definition: findings from the Hertfordshire Cohort Study (HCS). Age Ageing 42(3):378–384 PubMedCentralCrossRefPubMed
Rantanen T, Avlund K, Suominen H, Schroll M, Frandin K, Pertti E (2002) Muscle strength as a predictor of onset of ADL dependence in people aged 75 years. Aging Clin Exp Res 14(3 Suppl):10–15 PubMed
Rosenberg IH (1997) Sarcopenia: origins and clinical relevance. J Nutr 127(5 Suppl):990–991
von Haehling S, Morley JE, Anker SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachexia Sarcopenia Muscle 1(2):129–133 CrossRef
Prevalence and definition of sarcopenia in community dwelling older people
Data from the Berlin aging study II (BASE-II)
Dr. D. Spira
Priv.-Doz. Dr. K. Norman
MSc. J. Nikolov
Priv.-Doz. Dr. I. Demuth
Univ.-Prof. Dr. E. Steinhagen-Thiessen
Dr. R. Eckardt
- Springer Berlin Heidelberg